GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » E10

InMed Pharmaceuticals (InMed Pharmaceuticals) E10 : $-41.34 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

InMed Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.180. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-41.34 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -6.10% per year. During the past 5 years, the average E10 Growth Rate was 5.00% per year. During the past 10 years, the average E10 Growth Rate was 23.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of InMed Pharmaceuticals was 39.30% per year. The lowest was -6.10% per year. And the median was 18.85% per year.

As of today (2024-06-09), InMed Pharmaceuticals's current stock price is $0.2354. InMed Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-41.34. InMed Pharmaceuticals's Shiller PE Ratio of today is .


InMed Pharmaceuticals E10 Historical Data

The historical data trend for InMed Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals E10 Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -38.00 -34.29 -35.14 -39.48 -40.99

InMed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.59 -40.99 -41.37 -41.23 -41.34

Competitive Comparison of InMed Pharmaceuticals's E10

For the Biotechnology subindustry, InMed Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Shiller PE Ratio falls into.



InMed Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InMed Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.18/126.2576*126.2576
=-0.180

Current CPI (Mar. 2024) = 126.2576.

InMed Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -20.513 99.473 -26.036
201409 -14.783 99.394 -18.778
201412 -7.107 98.367 -9.122
201503 -26.029 99.789 -32.933
201506 -14.265 100.500 -17.921
201509 -6.145 100.421 -7.726
201512 -5.945 99.947 -7.510
201603 -6.356 101.054 -7.941
201606 -6.439 102.002 -7.970
201609 -6.275 101.765 -7.785
201612 -6.138 101.449 -7.639
201703 -6.186 102.634 -7.610
201706 -13.158 103.029 -16.125
201709 -6.650 103.345 -8.124
201712 -6.561 103.345 -8.016
201803 -6.388 105.004 -7.681
201806 -12.083 105.557 -14.453
201809 -12.771 105.636 -15.264
201812 -12.114 105.399 -14.511
201903 -12.358 106.979 -14.585
201906 -17.852 107.690 -20.930
201909 -13.500 107.611 -15.839
201912 -12.000 107.769 -14.059
202003 -9.750 107.927 -11.406
202006 -7.750 108.401 -9.027
202009 -7.750 108.164 -9.046
202012 -9.250 108.559 -10.758
202103 -10.250 110.298 -11.733
202106 -10.210 111.720 -11.539
202109 -6.170 112.905 -6.900
202112 -7.730 113.774 -8.578
202203 -6.140 117.646 -6.589
202206 -12.095 120.806 -12.641
202209 -4.060 120.648 -4.249
202212 -0.910 120.964 -0.950
202303 -0.600 122.702 -0.617
202306 0.280 124.203 0.285
202309 -0.760 125.230 -0.766
202312 -0.190 125.072 -0.192
202403 -0.180 126.258 -0.180

Add all the adjusted EPS together and divide 10 will get our e10.


InMed Pharmaceuticals  (NAS:INM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


InMed Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (InMed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Executives
Jonathan Tegge officer: Interim CFO 217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li officer: VP, Accounting and Controller 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric A Adams director, officer: President & CEO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Brenda Edwards officer: Interim CFO 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove director 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill officer: CFO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson officer: SVP & GM of BayMedica LLC 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler director 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu officer: Sr. VP, Pre-Clinical Res/Dev C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Michael Woudenberg officer: VP, Chem/Manufacturing/Control C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Mancini Alexandra Diane Janet officer: Sr VP, Clinical Reg Affairs C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4